Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

Huanjie Shao, Chun Gao, Haikuo Tang, Hao Zhang, Lewis Rowland Roberts, Bonnie L. Hylander, Elizabeth A. Repasky, Wen Wee Ma, Jingxin Qiu, Alex Adjei, Grace K. Dy, Chunrong Yu

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background & Aims: The mammalian target of rapamycin (mTOR) plays a pivotal role in hepatocellular carcinoma (HCC). Previous studies indicated that inhibition of mTORC1 enhanced histone deacetylase inhibitors (HDACis)-mediated anti-tumor activity, accompanied with feedback activation of AKT. Therefore, dual targeting of mTORC1/C2 should be more efficient in suppressing AKT activity and in enhancing the anti-tumor activity of HDACi in HCC. Methods: The interactions between mTOR kinase inhibitors (mTORKis) (i.e., Pp242, AZD8055, OSI027) and HDACis (i.e., SAHA, LBH589) were examined in vitro using HCC cell lines and in vivo using patient-derived primary HCC xenografts on SCID mice. Results: mTORKis significantly enhanced HDACi-induced apoptosis in HCC cells. The inhibition of both mTORC1/2 not only efficiently blocked mTORC1 signaling, but also abrogated AKT-feedback activation caused by selective mTORC1 inhibition. The co-treatment of mTORKi and HDACi further inhibited AKT signaling and upregulated Bim. Dysfunction of mTORC2 by shRNA significantly lowered the threshold of HDACi-induced cytotoxicity by abrogating AKT activation. Knockdown of AKT1 sensitized Pp242/HDACi-induced apoptosis and ectopic expression of constitutively active AKT1 abrogated the combination-induced cytotoxicity, indicating AKT plays a vital role in the combination-induced effects. Knockdown of Bim prevented Pp242/HDACis-induced cytotoxicity in HCC. Lastly, in vivo studies indicated that the combination of AZD8055 and SAHA almost completely inhibited tumor-growth, without obvious adverse effects, by abrogating AKT and upregulating Bim; while either agent alone shows only 30% inhibition in primary HCC xenografts. Conclusions: Our findings suggest that a combining-regimen of mTORKi and HDACi may be an effective therapeutic strategy for HCC.

Original languageEnglish (US)
Pages (from-to)176-183
Number of pages8
JournalJournal of Hepatology
Volume56
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Histone Deacetylase Inhibitors
Liver Neoplasms
Hepatocellular Carcinoma
Neoplasms
Phosphotransferases
Sirolimus
Heterografts
Apoptosis
In Vitro Techniques
mechanistic target of rapamycin complex 1
SCID Mice
Small Interfering RNA
Cell Line

Keywords

  • AKT
  • Apoptosis
  • Bim
  • HCC
  • HDAC inhibitor
  • mTOR kinase inhibitor

ASJC Scopus subject areas

  • Hepatology

Cite this

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. / Shao, Huanjie; Gao, Chun; Tang, Haikuo; Zhang, Hao; Roberts, Lewis Rowland; Hylander, Bonnie L.; Repasky, Elizabeth A.; Ma, Wen Wee; Qiu, Jingxin; Adjei, Alex; Dy, Grace K.; Yu, Chunrong.

In: Journal of Hepatology, Vol. 56, No. 1, 01.2012, p. 176-183.

Research output: Contribution to journalArticle

Shao, Huanjie ; Gao, Chun ; Tang, Haikuo ; Zhang, Hao ; Roberts, Lewis Rowland ; Hylander, Bonnie L. ; Repasky, Elizabeth A. ; Ma, Wen Wee ; Qiu, Jingxin ; Adjei, Alex ; Dy, Grace K. ; Yu, Chunrong. / Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. In: Journal of Hepatology. 2012 ; Vol. 56, No. 1. pp. 176-183.
@article{71c0cb6185e3456ba0fc88f45842c1ac,
title = "Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo",
abstract = "Background & Aims: The mammalian target of rapamycin (mTOR) plays a pivotal role in hepatocellular carcinoma (HCC). Previous studies indicated that inhibition of mTORC1 enhanced histone deacetylase inhibitors (HDACis)-mediated anti-tumor activity, accompanied with feedback activation of AKT. Therefore, dual targeting of mTORC1/C2 should be more efficient in suppressing AKT activity and in enhancing the anti-tumor activity of HDACi in HCC. Methods: The interactions between mTOR kinase inhibitors (mTORKis) (i.e., Pp242, AZD8055, OSI027) and HDACis (i.e., SAHA, LBH589) were examined in vitro using HCC cell lines and in vivo using patient-derived primary HCC xenografts on SCID mice. Results: mTORKis significantly enhanced HDACi-induced apoptosis in HCC cells. The inhibition of both mTORC1/2 not only efficiently blocked mTORC1 signaling, but also abrogated AKT-feedback activation caused by selective mTORC1 inhibition. The co-treatment of mTORKi and HDACi further inhibited AKT signaling and upregulated Bim. Dysfunction of mTORC2 by shRNA significantly lowered the threshold of HDACi-induced cytotoxicity by abrogating AKT activation. Knockdown of AKT1 sensitized Pp242/HDACi-induced apoptosis and ectopic expression of constitutively active AKT1 abrogated the combination-induced cytotoxicity, indicating AKT plays a vital role in the combination-induced effects. Knockdown of Bim prevented Pp242/HDACis-induced cytotoxicity in HCC. Lastly, in vivo studies indicated that the combination of AZD8055 and SAHA almost completely inhibited tumor-growth, without obvious adverse effects, by abrogating AKT and upregulating Bim; while either agent alone shows only 30{\%} inhibition in primary HCC xenografts. Conclusions: Our findings suggest that a combining-regimen of mTORKi and HDACi may be an effective therapeutic strategy for HCC.",
keywords = "AKT, Apoptosis, Bim, HCC, HDAC inhibitor, mTOR kinase inhibitor",
author = "Huanjie Shao and Chun Gao and Haikuo Tang and Hao Zhang and Roberts, {Lewis Rowland} and Hylander, {Bonnie L.} and Repasky, {Elizabeth A.} and Ma, {Wen Wee} and Jingxin Qiu and Alex Adjei and Dy, {Grace K.} and Chunrong Yu",
year = "2012",
month = "1",
doi = "10.1016/j.jhep.2011.07.013",
language = "English (US)",
volume = "56",
pages = "176--183",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

AU - Shao, Huanjie

AU - Gao, Chun

AU - Tang, Haikuo

AU - Zhang, Hao

AU - Roberts, Lewis Rowland

AU - Hylander, Bonnie L.

AU - Repasky, Elizabeth A.

AU - Ma, Wen Wee

AU - Qiu, Jingxin

AU - Adjei, Alex

AU - Dy, Grace K.

AU - Yu, Chunrong

PY - 2012/1

Y1 - 2012/1

N2 - Background & Aims: The mammalian target of rapamycin (mTOR) plays a pivotal role in hepatocellular carcinoma (HCC). Previous studies indicated that inhibition of mTORC1 enhanced histone deacetylase inhibitors (HDACis)-mediated anti-tumor activity, accompanied with feedback activation of AKT. Therefore, dual targeting of mTORC1/C2 should be more efficient in suppressing AKT activity and in enhancing the anti-tumor activity of HDACi in HCC. Methods: The interactions between mTOR kinase inhibitors (mTORKis) (i.e., Pp242, AZD8055, OSI027) and HDACis (i.e., SAHA, LBH589) were examined in vitro using HCC cell lines and in vivo using patient-derived primary HCC xenografts on SCID mice. Results: mTORKis significantly enhanced HDACi-induced apoptosis in HCC cells. The inhibition of both mTORC1/2 not only efficiently blocked mTORC1 signaling, but also abrogated AKT-feedback activation caused by selective mTORC1 inhibition. The co-treatment of mTORKi and HDACi further inhibited AKT signaling and upregulated Bim. Dysfunction of mTORC2 by shRNA significantly lowered the threshold of HDACi-induced cytotoxicity by abrogating AKT activation. Knockdown of AKT1 sensitized Pp242/HDACi-induced apoptosis and ectopic expression of constitutively active AKT1 abrogated the combination-induced cytotoxicity, indicating AKT plays a vital role in the combination-induced effects. Knockdown of Bim prevented Pp242/HDACis-induced cytotoxicity in HCC. Lastly, in vivo studies indicated that the combination of AZD8055 and SAHA almost completely inhibited tumor-growth, without obvious adverse effects, by abrogating AKT and upregulating Bim; while either agent alone shows only 30% inhibition in primary HCC xenografts. Conclusions: Our findings suggest that a combining-regimen of mTORKi and HDACi may be an effective therapeutic strategy for HCC.

AB - Background & Aims: The mammalian target of rapamycin (mTOR) plays a pivotal role in hepatocellular carcinoma (HCC). Previous studies indicated that inhibition of mTORC1 enhanced histone deacetylase inhibitors (HDACis)-mediated anti-tumor activity, accompanied with feedback activation of AKT. Therefore, dual targeting of mTORC1/C2 should be more efficient in suppressing AKT activity and in enhancing the anti-tumor activity of HDACi in HCC. Methods: The interactions between mTOR kinase inhibitors (mTORKis) (i.e., Pp242, AZD8055, OSI027) and HDACis (i.e., SAHA, LBH589) were examined in vitro using HCC cell lines and in vivo using patient-derived primary HCC xenografts on SCID mice. Results: mTORKis significantly enhanced HDACi-induced apoptosis in HCC cells. The inhibition of both mTORC1/2 not only efficiently blocked mTORC1 signaling, but also abrogated AKT-feedback activation caused by selective mTORC1 inhibition. The co-treatment of mTORKi and HDACi further inhibited AKT signaling and upregulated Bim. Dysfunction of mTORC2 by shRNA significantly lowered the threshold of HDACi-induced cytotoxicity by abrogating AKT activation. Knockdown of AKT1 sensitized Pp242/HDACi-induced apoptosis and ectopic expression of constitutively active AKT1 abrogated the combination-induced cytotoxicity, indicating AKT plays a vital role in the combination-induced effects. Knockdown of Bim prevented Pp242/HDACis-induced cytotoxicity in HCC. Lastly, in vivo studies indicated that the combination of AZD8055 and SAHA almost completely inhibited tumor-growth, without obvious adverse effects, by abrogating AKT and upregulating Bim; while either agent alone shows only 30% inhibition in primary HCC xenografts. Conclusions: Our findings suggest that a combining-regimen of mTORKi and HDACi may be an effective therapeutic strategy for HCC.

KW - AKT

KW - Apoptosis

KW - Bim

KW - HCC

KW - HDAC inhibitor

KW - mTOR kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=83555161682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555161682&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2011.07.013

DO - 10.1016/j.jhep.2011.07.013

M3 - Article

C2 - 21835141

AN - SCOPUS:83555161682

VL - 56

SP - 176

EP - 183

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -